摘要
目的探讨沙库巴曲缬沙坦钠联合达格列净对急性心肌梗死合并糖尿病患者的影响。方法选取赣南医学院第一附属医院2021年7月-2022年12月收治的60例急性心肌梗死合并糖尿病患者为研究对象,采用随机数字表法将纳入患者分成观察组和对照组,每组各30例。两组患者均予以常规治疗,对照组于常规治疗基础上加用马来酸依那普利,观察组于常规治疗基础上加用沙库巴曲缬沙坦钠联合达格列净,两组均维持12周治疗。比较两组心室重构相关指标、血糖指标、炎症指标、不良反应。结果观察组N末端脑钠肽前体(NT-proBNP)(1026.94±325.41)ng/L、糖化血红蛋白(HbA1c)(6.21±1.08)%、左室舒张末期内径(LVEDD)(44.35±3.71)mm、空腹血糖(FPG)(6.42±0.98)mmo1/L、餐后2h血糖(2hPG)(7.24±1.41)mmo1/L、C反应蛋白(CRP)(5.01±0.96)mg/L、细胞间黏附分子(ICAM-1)(171.28±9.54)ug/L、肿瘤坏死因子-α(TNF-α)(121.71±9.87)nmo1/L均低于对照组,左心室射血分数(LVEF)(49.11±6.84)%高于对照组,差异有统计学意义(P<0.05);观察组不良反应与对照组相当(P>0.05)。结论采用沙库巴曲缬沙坦钠联合达格列净治疗,可促进急性心肌梗死合并糖尿病患者机体内炎性反应减轻,调节血糖指标,延缓PCI术后心室重构,且安全性高。
Objective To investigate the effect of sakubactrovalsartan sodium combined with dagelin on patients with acute myocardial infarction complicated with diabetes.Methods 60 patients with acute myocardial infarction complicated with diabetes admitted to the hospital from July 2021 to December 2022 were selected as the research objects,and the patients were divided into the observation group and the control group by random number table method,with 30 cases in each group.Both groups of patients received routine treatment.The control group received enalapril maleate in addition to routine treatment,while the observation group received sacubitril valsartan sodium combined with dapagliflozin in addition to routine treatment.Both groups maintained treatment for 12 weeks.Compare two groups of ventricular remodeling related indicators,blood glucose indicators,inflammation indicators,and adverse reactions.Results In the observation group,N-terminal proBNP(1026.94±325.41)ng/L,glycated hemoglobin(HbA1c)(6.21±1.08)%,left ventricular end diastolic diameter(LVEDD)(44.35±3.71)mm,fasting blood glucose(FPG)(6.42±0.98)mmol/L,postprandial 2-hour blood glucose(2hPG)(7.24±1.41)mmol/L,C-reactive protein(CRP)(5.01±0.96)mg/L,and intercellular adhesion molecule(ICAM-1)(171.28±9.54)μg/L were observed,tumor necrosis factor-α(TNF-α)(121.71±9.87)nmol/L was lower than the control group,and the left ventricular ejection fraction(LVEF)was(49.11±6.84)%higher than the control group,with a statistically significant difference(P<0.05);the adverse reactions in the observation group were comparable to those in the control group(P>0.05).Conclusion Sacubatrovalsartan sodium combined with daggligin can reduce the inflammatory reaction in the body of patients with acute myocardial infarction complicated with diabetes,regulate blood glucose indicators,delay ventricular remodeling after PCI,and has high safety.
作者
刘金明
黄彩虹
赖性君
熊萍
Liu Jinming;Huang Caihong;Lai Xingjun;Xiong Ping(The First Affiliated Hospital of Gannan Medical College,Ganzhou,Jiangxi 341000,China)
出处
《首都食品与医药》
2024年第12期66-68,共3页
Capital Food Medicine
基金
赣州市指导性科技计划项目(GZ2021ZSF097)。
关键词
急性心肌梗死
糖尿病
达格列净
沙库巴曲缬沙坦钠
血糖
心室重构
炎症
Acute myocardial infarction
Diabetes
Dapagliflozin
Sacubitril valsartan sodium
Blood sugar
Ventricular remodeling
inflammation
